Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PUL-042 Inhalation Solution in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 May 2015
Price :
$35
*
At a glance
- Drugs ODN/Pam2 (Primary)
- Indications Influenza virus infections; Pneumonia
- Focus Adverse reactions
- Sponsors Pulmotect
- 28 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2014 New trial record